
Probing a 3,4â²-bis-guanidinium diaryl derivative as an allosteric inhibitor of the Ras pathway
Keywords: CRC; colorectal cancer; PK; protein kinase; PKI; protein kinase inhibitor; FDA; Federal Drug Agency; HL-60; acute myeloid leukaemia cell line; MTT; 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; IC50; half maximal inhibitory concentration;